Sphera Funds Management LTD. Acquires 14,625 Shares of Ascendis Pharma A/S (ASND)
Sphera Funds Management LTD. lifted its position in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 18.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 92,673 shares of the biotechnology company’s stock after acquiring an additional 14,625 shares during the period. Sphera Funds Management LTD. owned approximately 0.22% of Ascendis Pharma A/S worth $6,567,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. PNC Financial Services Group Inc. purchased a new stake in shares of Ascendis Pharma A/S during the 2nd quarter worth approximately $350,000. Quantitative Systematic Strategies LLC acquired a new stake in Ascendis Pharma A/S in the 2nd quarter valued at about $361,000. Meadow Creek Investment Management LLC grew its stake in Ascendis Pharma A/S by 12.1% in the 2nd quarter. Meadow Creek Investment Management LLC now owns 6,952 shares of the biotechnology company’s stock valued at $462,000 after acquiring an additional 748 shares during the last quarter. Glen Harbor Capital Management LLC grew its stake in Ascendis Pharma A/S by 12.1% in the 2nd quarter. Glen Harbor Capital Management LLC now owns 8,848 shares of the biotechnology company’s stock valued at $589,000 after acquiring an additional 952 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in Ascendis Pharma A/S by 153.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,444 shares of the biotechnology company’s stock valued at $598,000 after acquiring an additional 5,107 shares during the last quarter. 95.60% of the stock is owned by institutional investors.
Shares of NASDAQ ASND traded down $1.49 during midday trading on Friday, reaching $63.50. 1,170 shares of the company’s stock traded hands, compared to its average volume of 98,890. Ascendis Pharma A/S has a one year low of $36.07 and a one year high of $76.99. The company has a market cap of $2.72 billion, a PE ratio of -14.67 and a beta of 0.82.
ASND has been the subject of several recent research reports. ValuEngine upgraded shares of Ascendis Pharma A/S from a “buy” rating to a “strong-buy” rating in a report on Wednesday. Credit Suisse Group increased their price objective on Ascendis Pharma A/S from $80.00 to $86.00 and gave the company an “outperform” rating in a report on Thursday, November 29th. Zacks Investment Research lowered Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a report on Tuesday, November 13th. BidaskClub raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Friday, October 19th. Finally, Wedbush set a $79.00 target price on Ascendis Pharma A/S and gave the stock a “buy” rating in a research report on Thursday, August 30th. Three research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $77.56.
COPYRIGHT VIOLATION WARNING: “Sphera Funds Management LTD. Acquires 14,625 Shares of Ascendis Pharma A/S (ASND)” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.watchlistnews.com/sphera-funds-management-ltd-acquires-14625-shares-of-ascendis-pharma-a-s-asnd/2668564.html.
Ascendis Pharma A/S Profile
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.
Further Reading: Market Capitalization in the Stock Market
Want to see what other hedge funds are holding ASND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ascendis Pharma A/S (NASDAQ:ASND).
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.